Bone Biologics Corporation Price & Performance (BBLG)

Bone Biologics shares dropped 16.3% on Friday, extending a sharp downward trend that has seen the company's value fall over 50% in the past year. The decline follows persistent concerns about the company’s cash reserves, Nasdaq compliance issues, and uncertainty about its ability to fund ongoing operations.123

The FDA has approved Fresenius Kabi Biopharma’s denosumab biosimilars, Conexxence and Bomyntra, for all indications of Prolia and Xgeva. The decision, part of a global settlement with Amgen, will allow U.S. launches in mid-2025, potentially increasing patient access to affordable osteoporosis and bone metastases therapies.456

Bone Biologics has scheduled its 2025 annual stockholder meeting for May 30, more than a month earlier than last year. The move comes as the firm faces a depressed stock price, tightened SEC deadlines, and heightened scrutiny over its financial health and compliance with Nasdaq listing standards.789